231 episodes

This podcast delivers Dr. John Mandrola’s summary and perspective on top news of the week that cardiologists can’t miss. This podcast is intended for US health professionals only.

This Week in Cardiology Medscape

    • Science
    • 4.9 • 525 Ratings

This podcast delivers Dr. John Mandrola’s summary and perspective on top news of the week that cardiologists can’t miss. This podcast is intended for US health professionals only.

    Sep 23, 2022 This Week in Cardiology Podcast

    Sep 23, 2022 This Week in Cardiology Podcast

    In this week’s podcast, John Mandrola, MD, discusses the PROTECTED TAVR trial, renal denervation, left atrial appendage closure and deprescribing aspirin.
    This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
    I Cerebral Embolic Protection After TAVI
    - Clear Stroke Benefit Eludes Embolic Protection: PROTECTED TAVR https://www.medscape.com/viewarticle/980978
    - Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement https://www.nejm.org/doi/10.1056/NEJMoa2204961
    - Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement https://doi.org/10.1016/j.jacc.2016.10.023
    - Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
    - Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
    - Randomised Trial Of Intravenous Streptokinase, Oral Aspirin, Both, Or Neither Among 17 187 Cases Of Suspected Acute Myocardial Infarction: Isis-2 https://doi.org/10.1016/S0140-6736(88)92833-4
    II Renal Denervation
    - Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
    - Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial https://doi.org/10.1016/S0140-6736(22)01787-1
    - A systematic review, meta-analysis, and meta regression of the sham controlled renal denervation randomized controlled trials https://doi.org/10.1016/j.tcm.2022.05.009
    - Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
    - A Controlled Trial of Renal Denervation for Resistant Hypertension https://www.nejm.org/doi/10.1056/NEJMoa1402670
    III Percutaneous Left Atrial Appendage Occlusion (LAAO)
    - Amulet, Watchman 2.5 LAAO Outcomes Neck and Neck at 3 Years https://www.medscape.com/viewarticle/981199
    - Consider Life Expectancy When Referring for LAA Closure? https://www.medscape.com/viewarticle/981117
    - Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/full/10.1016/j.jacep.2022.06.012
    IV Deprescribing Aspirin
    - Deprescribing Aspirin for Warfarin Patients May Reduce Bleeding https://www.medscape.com/viewarticle/981243
    - Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796492
    You may also like:
    Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
    The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
    Questions or feedback, please contact news@medscape.net

    • 27 min
    Sept 16, 2022 This Week in Cardiology Podcast

    Sept 16, 2022 This Week in Cardiology Podcast

    The safety of very low LDL-C, the win-ratio analytic method, sacubitril/valsartan, SGLT2 inhibitors, and percutaneous left atrial appendage closure are discussed in this week’s podcast.
    This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
    https://www.medscape.com/twic
    I PCSK9I
    Evolocumab Benefits Accrue With Longer Follow-up: FOURIER OLE
    https://www.medscape.com/viewarticle/979950
    - Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
    https://www.nejm.org/doi/full/10.1056/nejmoa1615664
    - Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
    https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061620
    II Analytic Methods and Re-Analysis of Old Trials
    - PARADISE-MI Results Obscured As Post Hoc Analysis Finds Flaws
    https://www.medscape.com/viewarticle/980776
    - Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction
    https://www.nejm.org/doi/10.1056/NEJMoa2104508
    - Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial
    https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057429
    - The Year’s Most Important Study Adds to Uncertainty in Science
    https://www.medscape.com/viewarticle/904286
    III SGLT2i Post MI
    - Early Signal of Benefit for Empagliflozin in Acute MI: EMMY
    https://www.medscape.com/viewarticle/980180
    - Empagliflozin in acute myocardial infarction: the EMMY trial
    https://doi.org/10.1093/eurheartj/ehac494
    IV Percutaneous Left Atrial Appendage Closure
    - Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure
    https://www.jacc.org/doi/10.1016/j.jacep.2022.06.012
    - Cost‐Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5‐Year, Long‐Term Data
    https://www.ahajournals.org/doi/10.1161/JAHA.118.011577
    - Baseline Comorbidities And Bleeding Events Of Patients Undergoing Percutaneous Left Atrial Appendage Occlusion Among Medicare Beneficiaries
    https://www.jacc.org/doi/10.1016/S0735-1097%2822%2901158-5
    You may also like:
    Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
    https://www.medscape.com/features/public/machine
    The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
    https://www.medscape.com/author/bob-harrington
    Questions or feedback, please contact news@medscape.net

    • 23 min
    Sep 9, 2022 This Week in Cardiology Podcast

    Sep 9, 2022 This Week in Cardiology Podcast

    A potential new anticoagulant, surveillance stress testing, a trial misinterpretation, an old diuretic, and AI in cardiology are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
    I. Factor XI inhibitors
    - Factor XIa Inhibitor After MI, Stroke Encouraging in Early Phase 2 Studies https://www.medscape.com/viewarticle/979942
    - AXIOMATIC-SSP: Cautious Optimism on Factor XI Inhibitor in Stroke https://www.medscape.com/viewarticle/979860
    II. Surveillance Stress Testing
    - No Benefit of Routine Stress Test POST-PCI in High-Risk Patients https://www.medscape.com/viewarticle/979866
    - Routine Functional Testing or Standard Care in High-Risk Patients after PCI https://www.nejm.org/doi/full/10.1056/NEJMoa2208335
    III. New Diuretic for Acute Heart Failure
    - Vintage Drug Atop IV Loop Diuretics Boosts Decongestion in ADHF: ADVOR https://www.medscape.com/viewarticle/979851
    - Acetazolamide in Acute Decompensated Heart Failure with Volume Overload https://www.nejm.org/doi/full/10.1056/NEJMoa2203094
    IV. AI in Cardiology
    - In Blinded Trial, Artificial Intelligence Beats Sonographers for Echo Accuracy https://www.medscape.com/viewarticle/979857
    - Video-based AI for beat-to-beat assessment of cardiac function https://www.nature.com/articles/s41586-020-2145-8
    You may also like:
    Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
    The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
    Questions or feedback, please contact news@medscape.net

    • 24 min
    Sep 2 2022 This Week in Cardiology Podcast

    Sep 2 2022 This Week in Cardiology Podcast

    A second ESC review covering REVIVED, the DANCAVAS CV screening trial, DELIVER on dapagliflozin in HF with mildly reduced EF, and the INVICTUS trial of rivaroxaban in rheumatic heart disease. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
    I REVIVED BCIS
    - PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 https://www.medscape.com/viewarticle/979853
    - Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
    - Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/nejmoa1100356
    II DANCAVAS
    - DANCAVAS Misses Primary Endpoint but Hints at Benefit from Comprehensive CV Screening https://www.medscape.com/viewarticle/979854
    - Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
    - Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1608029
    III DELIVER Trial
    - Dapagliflozin's HFpEF Benefit Recasts Heart Failure Treatment: DELIVER https://www.medscape.com/viewarticle/979855
    - Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
    - Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
    - SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials https://doi.org/10.1016/S0140-6736(22)01429-5
    IV Rheumatic Heart Disease
    - Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease https://www.medscape.com/viewarticle/979861
    - Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa2209051
    - Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve https://www.nejm.org/doi/full/10.1056/NEJMoa2029603
    - Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis https://www.jacc.org/doi/full/10.1016/j.jacc.2018.12.047
    Features:
    - Do SGLT2 Inhibitors DELIVER in All Patients With Heart Failure? https://www.medscape.com/viewarticle/979852
    - PCI Fails in Stable Disease Again: REVIVED-BCIS https://www.medscape.com/viewarticle/979862
    - DANCAVAS: Might Cardiovascular Screening Extend Men's Lives? https://www.medscape.com/viewarticle/979632
    You may also like:
    Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
    The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
    Questions or feedback, please contact news@medscape.net

    • 25 min
    Aug 26, 2022 This Week in Cardiology Podcast

    Aug 26, 2022 This Week in Cardiology Podcast

    Early rhythm control in AF, treating coronary artery disease before transcatheter aortic valve implantation, and an ESC 2022 preview are the topics John Mandrola, MD, covers in this week’s podcast.
    This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
    I. Early Rhythm Control
    - Early AF Rhythm-Control Advantage Climbs With Comorbidity Burden: EAST-AFNET4 https://www.medscape.com/viewarticle/979627
    - Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.122.060274
    Early Rhythm-Control Therapy in Patients with Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
    II. CAD and Aortic Stenosis
    - No Survival Gains Seen From Pre-TAVR PCI of Complex CAD https://www.medscape.com/viewarticle/979408
    - The Effect of Coronary Lesion Complexity and Preprocedural Revascularization on 5-Year Outcomes After TAVR https://doi.org/10.1016/j.jcin.2022.06.019
    - Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta‐Analysis https://www.ahajournals.org/doi/10.1161/JAHA.117.005960
    - ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic Valve implantaTION): A Randomized Clinical Trial https://www.jacc.org/doi/full/10.1016/j.jcin.2021.06.041
    III. ESC Trials
    - Mandrola Previews His Top 5 Trials From ESC 2022 https://www.medscape.com/viewarticle/979560
    TIME
    - Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension https://pubmed.ncbi.nlm.nih.gov/35983870/
    - Empirical Evaluation of Very Large Treatment Effects of Medical Interventions https://jamanetwork.com/journals/jama/fullarticle/1386610
    SECURE
    - Polypill Strategy in Secondary Cardiovascular Prevention http://www.nejm.org/doi/full/10.1056/NEJMoa2208275CAPLA
    - Catheter ablation for persistent atrial fibrillation: A multicenter randomized trial of pulmonary vein isolation (PVI) versus PVI with posterior left atrial wall isolation (PWI) - The CAPLA study http://www.sciencedirect.com/science/article/pii/S0002870321002453?via%3Dihub
    IV. ESC Preview
    - Barcelona Beckons for First Hybrid ESC Congress https://www.medscape.com/viewarticle/979477
    You may also like:
    Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
    The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
    Questions or feedback, please contact news@medscape.net

    • 26 min
    Aug 19, 2022 This Week in Cardiology Podcast

    Aug 19, 2022 This Week in Cardiology Podcast

    The obesity paradox in AF and paradoxes in general, digital health gets whacked again, and direct-to-consumer ads are the topics discussed by John Mandrola, MD in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
    I. Collider Bias and the Obesity Paradox
    - 'Obesity Paradox' in Atrial Fibrillation Challenged as Mortality Climbs With BMI https://www.medscape.com/viewarticle/979150
    - Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF https://openheart.bmj.com/content/9/2/e002038
    - Collider bias https://catalogofbias.org/biases/collider-bias/
    - Pediatric obesity appears to lower the risk of diabetes if selection bias is ignored https://pubmed.ncbi.nlm.nih.gov/29374028/
    - Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2480484
    II. Digital Health
    - Blood Pressure Smartphone App Fails to Beat Standard Self-Monitoring https://www.medscape.com/viewarticle/979341
    - Effectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2794971
    III. Direct-to-Consumer Ads
    - Does DTC Heart Drug Advertising Discourage Lifestyle Changes? https://www.medscape.com/viewarticle/979404
    - Association of Direct-to-Consumer Advertising of Prescription Drugs With Consumer Health-Related Intentions and Beliefs Among Individuals at Risk of Cardiovascular Disease https://jamanetwork.com/journals/jama-health-forum/fullarticle/2794995
    You may also like:
    Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
    The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
    Questions or feedback, please contact news@medscape.net

    • 22 min

Customer Reviews

4.9 out of 5
525 Ratings

525 Ratings

careful dictor ,

Helpful appraisal of cardiology literature

Clinical practice should be evidence based.

qortyf ,

Great Review For Primary Care

The studies are reviewed logically. The presenter clearly shows how the results can be applied to clinical practice.

nattannattan ,

Fantastic

Dr Mandrola provides superior, unbiased analysis and interpretation. I always find important applicable information for my practice. Thank you Dr. Mandrola!

You Might Also Like

American College of Cardiology
American College of Cardiology
CardioNerds
JAMA Network
Core IM Team
The New England Journal of Medicine

More by Medscape

Medscape
Medscape Podcasts
Medscape
Medscape
Medscape